Menu

Report selector

Aspen 2019 IAR report cover
Who we
Currently viewing: Who we/ Home | Next: Our approach to reporting

About Aspen

Our values

define the foundation on which Aspen has been built. These are the values we share as we work together toward achieving the vision of the Group

View more about Aspen
Approximately

10 000

employees in 70 businesses across 55 countries

48%

Women

52%

Men
Total revenue

R38,9
billion

continuing operations
  • Our geographic footprint

    Headquartered in South Africa, we have a global commercial presence in both emerging and developed markets.

    56%

    of Commercial Pharmaceutical revenue from emerging markets
  • Our manufacturing capabilities

    Our manufacturing capabilities span a wide variety of product types including injectables, oral solid dose, liquids, semi-solids, steriles, biologicals and active pharmaceutical ingredients (“APIs”). Our manufacturing sites hold international approvals from some of the most stringent global regulatory agencies.

    8

    Active pharmaceutical ingredient facilities

    15

    Finished dose form facilities

  • Our commitment to sustainability

    We are committed to creating value for all of our stakeholders in a manner that is responsible, transparent and respects the rights of all.

    FTSE/JSE Responsible Investment Index
    constituent

Strategic objectives

Our business segments

Our strategic objectives provide the framework for our plan of action to achieve our short, medium and long-term goals. An analysis of these strategic objectives and KPIs is set out in this Integrated Report.

To enhance access to high quality, affordable medicines

To achieve strategic advantage through our integrated supply chain

To provide a safe, challenging and rewarding environment for our employees

To practise good corporate citizenship

To create sustainable economic value for all our stakeholders

View strategic objectives

We focus on marketing a broad range of post-patent, branded medicines and domestic brands covering both hospital and consumer markets through our key business segments:

Commercial Pharmaceuticals

Regional Brands – a widely diverse segment comprising predominantly leading domestic brands in the Sub-Saharan Africa, Australasia and Latin American territories.

Sterile Focus Brands – focused on niche, sterile products comprising our Anaesthetics Brands and Thrombosis Brands.

Anaesthetics – includes a broad range of general anaesthetics, muscle relaxants as well as a number of local anaesthetics including topical agents.

Thrombosis – comprises a broad range of specialist injectable anticoagulants with a focus on low molecular weight heparins, Xa inhibitors and heparin derivatives.

Contribution to Group revenue

46%

Contribution to Group revenue

39%

Manufacturing

Contract and supply of chemical and biochemical APIs and finished dose form pharmaceuticals (“FDF”) for third parties.

View our business segments

Contribution to Group revenue

15%

The value we create

As a global pharmaceutical company, we play an important role in contributing to the health and wellbeing of people. Our sustainable business model creates long-term value for our key stakeholders.

View the value we create

Our investment case

Responsible corporate citizen and a trusted partner

Strategically relevant manufacturing capital

Global footprint with a focus on emerging markets

Diverse, branded product portfolio

Committed management team, strongly aligned with shareholders' interests

View our investment case

Chairman's statement

Kuseni Dlamini

Chairman

As Aspen continues to consolidate its position as a global pharmaceutical company, operating in a dynamic and uncertain global context, the Board’s focus for the year has been on adapting the Group’s strategy to an environment where businesses are increasingly being required to deliver satisfactory returns, while operating in a socially responsible and conscientious manner.

Given these circumstances, I am pleased to report that Aspen has achieved most of its short-term goals and has developed plans to unlock further...

View chairman's statement